TriMas (NASDAQ:TRS – Get Free Report) released its earnings results on Thursday. The industrial products company reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.48 by ($0.05), Zacks reports. TriMas had a return on equity of 9.21% and a net margin of 2.93%. TriMas updated its FY 2025 guidance to 1.700-1.850 EPS.
TriMas Stock Performance
TriMas stock traded down $1.36 during trading hours on Thursday, reaching $20.51. 1,158,029 shares of the company were exchanged, compared to its average volume of 334,114. The firm has a market cap of $832.13 million, a price-to-earnings ratio of 32.05 and a beta of 0.66. The company has a current ratio of 2.83, a quick ratio of 1.44 and a debt-to-equity ratio of 0.60. The stock has a 50-day moving average of $23.95 and a 200 day moving average of $25.15. TriMas has a 12 month low of $19.33 and a 12 month high of $28.51.
TriMas Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 28th will be issued a $0.04 dividend. The ex-dividend date is Friday, February 28th. This represents a $0.16 dividend on an annualized basis and a yield of 0.78%. TriMas’s dividend payout ratio is currently 25.00%.
Analysts Set New Price Targets
Check Out Our Latest Analysis on TRS
TriMas Company Profile
TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace, and industrial markets worldwide. The company operates through Packaging, Aerospace, and Specialty Products segments. The Packaging segment offers dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, and flexible spouts; polymeric jar products; integrated dispensers; bag-in-box products; and consumable vascular delivery and diagnostic test components under the Rieke, Taplast, Affaba & Ferrari, Intertech, Omega, and Rapak brands.
See Also
- Five stocks we like better than TriMas
- Options Trading – Understanding Strike Price
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- What is the S&P/TSX Index?
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Top Biotech Stocks: Exploring Innovation Opportunities
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for TriMas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriMas and related companies with MarketBeat.com's FREE daily email newsletter.